Date:8/18/2009

cial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

    CONTACT:
    Catherine Lemercier              Gary Nash
    OmniComm Systems, Inc.           CEOcast, Inc. for OmniComm
    954-473-1254 Extension 283       212-732-4300
    clemercier@omnicomm.com          gnash@ceocast.com

    Stephen Johnson
    954-377-1726

'/>"/>

SOURCE OmniComm Systems, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
2. Clinical Study Proves Pollogens TriPollar(TM) Radio Frequency Technology is Effective in the Treatment of Stretch Marks
3. OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
4. ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology
5. ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients
6. Radius Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis
7. Project Zero Delay Accelerates Drugs Path to Clinical Trial
8. Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program
9. Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression
10. Terumo Cardiovascular Systems Initiates U.S. Clinical Trial for Anaconda(TM) AAA Stent Graft System
11. R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent